Purpose To evaluate the effects of aflibercept administered according to a pro re nata (PRN) or Fixed Regimen to patients with neovascular AMD and persistent intraretinal/subretinal fluid (IRF/SRF) despite three consecutive ranibizumab injections.MethodsPatients were switched to aflibercept injection (IVA) administered according to a PRN or to a fixed regimen for 1 year in two different retina centers. At baseline each patient underwent a complete ophthalmologic evaluation, including best-corrected visual acuity assessment (BCVA ETDRS chart), fluorescein, and indocyanine green angiography and OCT.ResultsEach group included 36 eyes. After 1 year the PRN group showed BCVA stabilization (63 vs 60 letters, P=0.33), whereas fixed regimen group showed significant BCVA improvement (68 vs 71, P=0.008). The median central retinal thickness decreased by 94 μm in the PRN (P=0.002) and by 148 μm in the fixed regimen group (P≤0.001). Complete IRF/SRF reabsorption was found in 58% of eyes in the PRN and in 42% of eyes in the fixed regimen group. At 1-year visit, the percentage of eyes with pigment epithelium detachment did not significantly decrease, but a height reduction was recorded in both groups. The median number of IVA was 3.5 in the PRN and 7 in the fixed regimen group.ConclusionThe switch to aflibercept with both treatment strategies enabled improvement in morphological parameters and stabilization of visual acuity. BCVA improvement and reduction in vision loss with reduction in retinal thickness, fluid and PED height was achieved with the fixed regimen in previously treated nAMD after 1 year.

Ricci, F., F., A.p., M., A.r., F., A.s., M., A.t., M., A.m., et al. (2016). Aflibercept in persistent neovascular AMD: Comparison of different treatment strategies in switching therapy. EYE, 30(8), 1077-1083 [10.1038/eye.2016.95].

Aflibercept in persistent neovascular AMD: Comparison of different treatment strategies in switching therapy

Ricci;
2016-01-01

Abstract

Purpose To evaluate the effects of aflibercept administered according to a pro re nata (PRN) or Fixed Regimen to patients with neovascular AMD and persistent intraretinal/subretinal fluid (IRF/SRF) despite three consecutive ranibizumab injections.MethodsPatients were switched to aflibercept injection (IVA) administered according to a PRN or to a fixed regimen for 1 year in two different retina centers. At baseline each patient underwent a complete ophthalmologic evaluation, including best-corrected visual acuity assessment (BCVA ETDRS chart), fluorescein, and indocyanine green angiography and OCT.ResultsEach group included 36 eyes. After 1 year the PRN group showed BCVA stabilization (63 vs 60 letters, P=0.33), whereas fixed regimen group showed significant BCVA improvement (68 vs 71, P=0.008). The median central retinal thickness decreased by 94 μm in the PRN (P=0.002) and by 148 μm in the fixed regimen group (P≤0.001). Complete IRF/SRF reabsorption was found in 58% of eyes in the PRN and in 42% of eyes in the fixed regimen group. At 1-year visit, the percentage of eyes with pigment epithelium detachment did not significantly decrease, but a height reduction was recorded in both groups. The median number of IVA was 3.5 in the PRN and 7 in the fixed regimen group.ConclusionThe switch to aflibercept with both treatment strategies enabled improvement in morphological parameters and stabilization of visual acuity. BCVA improvement and reduction in vision loss with reduction in retinal thickness, fluid and PED height was achieved with the fixed regimen in previously treated nAMD after 1 year.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/30
English
aflibercept; fluorescein; indocyanine green; ranibizumab; aflibercept; angiogenesis inhibitor; hybrid protein; ranibizumab; vasculotropin A; vasculotropin receptor; VEGFA protein, human, adult; age related macular degeneration; aged; Article; central retinal thickness; clinical article; clinical evaluation; controlled study; drug efficacy; drug substitution; drug withdrawal; eye disease; female; follow up; human; indocyanine green angiography; loading drug dose; male; polypoidal choroidal vasculopathy; recommended drug dose; retina detachment; retina neovascularization; retrospective study; spectral domain optical coherence tomography; subretinal fluid; systemic disease; visual acuity; antagonists and inhibitors; clinical trial; comparative study; fluorescence angiography; intravitreal drug administration; middle aged; multicenter study; optical coherence tomography; pathophysiology; physiology; very elderly; wet macular degeneration, Aged; Aged, 80 and over; Angiogenesis Inhibitors; Drug Substitution; Female; Fluorescein Angiography; Humans; Intravitreal Injections; Male; Middle Aged; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Subretinal Fluid; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84982181964&doi=10.1038/eye.2016.95&partnerID=40&md5=a80880b0ddf23107e5cb31642f563802
Ricci, F., F., A.p., M., A.r., F., A.s., M., A.t., M., A.m., et al. (2016). Aflibercept in persistent neovascular AMD: Comparison of different treatment strategies in switching therapy. EYE, 30(8), 1077-1083 [10.1038/eye.2016.95].
Ricci, F; F., Ap; M., Ar; F., As; M., At; M., Am; F., Av
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/242453
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 9
social impact